The AI workspace for legal professionals
- Legal research with access to more than 1 million sources
- Document automation
- Matter management
- Hosted in the EU and Switzerland
Try it free for 14 days (10 questions/day during trial)
The AI workspace for legal professionals
Try it free for 14 days (10 questions/day during trial)
2011-1399•1409 in Re Cyclobenzaprine Hydrochloride Extended- Release Capsule Patent Litigation… v. MYLAN PHARMACEUTICALS INC. and MYLAN INC.
2011-1399Court of Appeals for the Federal CircuitMay 1, 2012
United States Court of Appeals
for the Federal Circuit
______________________
May 1, 2012
ERRATA
______________________
Appeal Nos. 2011-1399, -1409
IN RE CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-
RELEASE CAPSULE PATENT LITIGATION
---------------------------------------------------------------------------------
EURAND, INC., CEPHALON, INC., and ANESTA AG,
Plaintiffs-Cross Appellants,
v.
MYLAN PHARMACEUTICALS INC. and MYLAN INC.,
Defendants-Appellants,
and
BARR LABORATORIES, INC., TEVA PHARMACEUTICALS USA,
INC., and TEVA PHARMACEUTICAL INDUSTRIES LTD.,
Defendants-Appellees.
______________________
Decided: April 16, 2012
Precedential Opinion
______________________
Please make the following additions:
Page 2, Of counsel on the brief for plaintiff-cross appellant was Tryn T.
Stimart, Cooley Godward Kronish LLP, of Washington, DC.
Robert L. Byer, Duane Morris LLP, of Pittsburg, Pennsylvania, for
amici curiae Gregory Dolin and Robert C. Kahrl. With him on the
brief were Kristina Caggiano and Elese Hanson.
-- 1 of 1 --
Connect Omnilex to search the legal corpus from your AI assistant.